HLVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HLVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HilleVax's EBITDA for the three months ended in Sep. 2024 was $-23.13 Mil. HilleVax's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, HilleVax's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.
The historical data trend for HilleVax's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EBITDA Margin % | - | - | - | - |
HilleVax Quarterly Data | ||||||||||||||||
Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EBITDA Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, HilleVax's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, HilleVax's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HilleVax's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
HilleVax's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
HilleVax's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax (NAS:HLVX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of HilleVax's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Aditya Kohli | director, officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Frazier Life Sciences X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Astrid Borkowski | officer: Chief Medical Officer | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109 |
Robert Hershberg | director, officer: President and CEO | 3005 FIRST AVENUE, SEATTLE WA 98121 |
Shane Maltbie | officer: Chief Financial Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Nanette Cocero | director | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109 |
Fhmls X, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Gary Dubin | director | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109 |
Jaime Sepulveda | director | C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109 |
Takeda Vaccines, Inc. | 10 percent owner | 75 SIDNEY STREET, CAMBRIDGE MA 02139 |
Shelley Chu | director | ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110 |
Susan Michele Silbermann | director | C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540 |
Fhmls X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Julie L. Gerberding | director | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
David A Socks | officer: CFO & Chief Business Officer | C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
From GuruFocus
By Marketwired • 07-12-2024
By Marketwired • 07-14-2024
By GuruFocus Research • 04-06-2024
By Business Wire • 07-15-2024
By GuruFocus Research • 03-21-2024
By GuruFocus Research • 11-21-2023
By Business Wire • 07-08-2024
By Marketwired • 07-26-2024
By Marketwired • 07-31-2024
By Marketwired • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.